New molecular imaging agent traces advanced prostate cancer

the Oncology Nurse Advisor take:

Antiandrogen hormonal therapy can be an important part of preventing further disease progression for patients with metastatic prostate cancer. However, some cancers do not respond to the treatment. An imaging technique developed at Johns Hopkins University in Baltimore, Maryland, F-18 DCFBC PET/CT, uses a unique small-molecule PET agent to search for and attach to prostate-specific membrane antigen. The technique was developed in an effort to improve clinical decision making for patients who are not responding to androgen deprivation therapy.